C WorldWide Group Holding A S decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 36.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 103,781 shares of the biotechnology company’s stock after selling 60,704 shares during the period. C WorldWide Group Holding A S’s holdings in BioMarin Pharmaceutical were worth $9,425,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of BMRN. Cigna Investments Inc. New raised its position in shares of BioMarin Pharmaceutical by 1.5% in the second quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock worth $216,000 after buying an additional 36 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of BioMarin Pharmaceutical by 1.0% in the second quarter. Daiwa Securities Group Inc. now owns 4,950 shares of the biotechnology company’s stock worth $450,000 after buying an additional 50 shares in the last quarter. NGAM Advisors L.P. raised its position in shares of BioMarin Pharmaceutical by 0.4% in the second quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock worth $1,385,000 after buying an additional 55 shares in the last quarter. Grandfield & Dodd LLC raised its position in shares of BioMarin Pharmaceutical by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 5,727 shares of the biotechnology company’s stock worth $503,000 after buying an additional 65 shares in the last quarter. Finally, First American Trust FSB raised its position in shares of BioMarin Pharmaceutical by 0.3% in the second quarter. First American Trust FSB now owns 26,696 shares of the biotechnology company’s stock worth $2,424,000 after buying an additional 73 shares in the last quarter. 96.82% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at 81.96 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $102.06. The company’s market cap is $14.36 billion. The company’s 50 day moving average price is $89.42 and its 200 day moving average price is $89.99.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $317.50 million during the quarter, compared to analysts’ expectations of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.61) earnings per share. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post ($0.71) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-9-43-million-position-in-biomarin-pharmaceutical-inc-bmrn/1474467.html.

A number of research analysts have recently commented on the company. BidaskClub lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and set a $116.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday, May 15th. Stifel Nicolaus reissued a “buy” rating and set a $107.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, August 4th. Wedbush reissued a “neutral” rating and set a $108.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday. Finally, Cowen and Company reissued a “buy” rating and set a $150.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday, May 15th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $110.20.

In related news, EVP George Eric Davis sold 9,471 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $91.04, for a total value of $862,239.84. Following the completion of the sale, the executive vice president now directly owns 74,342 shares in the company, valued at $6,768,095.68. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Brian Mueller sold 2,671 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $267,100.00. Following the completion of the sale, the senior vice president now owns 15,556 shares of the company’s stock, valued at $1,555,600. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,740 shares of company stock valued at $5,659,589. 2.50% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.